8-K
filed November 9, 2022, 6:59 PM ET
ticker BRTX
CIK 0001505497
other material
confidence high
sentiment neutral
materiality 0.15
BioRestorative shareholders approve all proposals, including reincorporation to Nevada
BioRestorative Therapies, Inc.
- Elected David Rosa and Francisco Silva as Class II directors; 1.8M and 1.95M shares for, respectively.
- Approved amendments to 2021 Stock Incentive Plan: 1.79M for, 163K against.
- Authorized reincorporation from Delaware to Nevada: 1.95M for, 12K against.
- Non-binding advisory vote approved executive compensation; future vote recommended every three years.
- Ratified Marcum LLP as independent auditor for FY2022: 2.64M for, 16K against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 at the 2022-11-03 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
6. Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For 2,636,553 Against 15,926 Abstentions 3,530
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Election of Class II Directors at the 2022-11-03 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
1. Election of Class II Directors: Number of Shares For Withheld Broker Non-Votes David Rosa 1,812,382 159,781 683,846 Francisco Silva 1,951,117 21,046 683,846
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation at the 2022-11-03 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
5. Recommendation, on a non-binding advisory basis, as to frequency of future advisory votes on the Company’s executive compensation: Three Years 1,768,754 Two Years 18,440 One Year 171,693 Abstentions 13,276
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Approval of amendments to the Company’s 2021 Stock Incentive Plan at the 2022-11-03 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
2. Approval of amendments to the Company’s 2021 Stock Incentive Plan: For 1,790,399 Against 163,058 Abstentions 18,706 Broker Non-Votes 683,846
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers at the 2022-11-03 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
4. Approval, on a non-binding advisory basis, of the compensation of the Company’s executive officers: For 1,785,569 Against 169,088 Abstentions 17,506 Broker Non-Votes 683,846
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
BioRestorative Therapies, Inc. shareholders approved Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada at the 2022-11-03 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2022-11-03
Exact text from the filing
3. Authorization of the reincorporation of the Company from the State of Delaware to the State of Nevada: For 1,954,622 Against 12,382 Abstentions 5,159 Broker Non-Votes 683,846
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.